Drug Information

Drug General Information
Drug ID
D07QFU
Former ID
DIB011212
Drug Name
T-607
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 2 [521548]
Company
Tularik Inc
Formula
C5H11NOS3
CAS Number
CAS 261944-52-9
PubChem Compound ID
462014
Target and Pathway
Target(s) Tubulin beta Target Info Inhibitor [551628]
KEGG Pathway Phagosome
Gap junction
Pathogenic Escherichia coli infection
NetPath Pathway FSH Signaling Pathway
TCR Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Cytoskeletal regulation by Rho GTPase
Huntington disease
Reactome Regulation of PLK1 Activity at G2/M Transition
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Anchoring of the basal body to the plasma membrane
WikiPathways Parkin-Ubiquitin Proteasomal System pathway
Pathogenic Escherichia coli infection
Mitotic G2-G2/M phases
References
Ref 521548ClinicalTrials.gov (NCT00054249) T900607 in Treating Patients With Gastroesophageal Junction Cancer. U.S. National Institutes of Health.
Ref 551628Nucleophilic reactions of N-ethoxycarbonyliminopyridinium ylide with alpha,beta-unsaturated carbonyl compounds. Volume 28, Issue 6, 1972, Pages 1469-1476.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.